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Objectives: The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) is a brief 
multi-domain assessment designed for people with Amyotrophic Lateral Sclerosis (ALS). 
This study evaluated the clinical impact of using the ECAS on ALS patients, carers and 
healthcare professionals. A secondary aim was to evaluate the clinical impact of 
neuropsychological intervention. Methods: A survey of current screening practices in 
ALS services across the UK was undertaken. In addition comparative case studies, in 
seven ALS care contexts, was qualitatively explored through interviews with patients, 
carers and healthcare professionals. Results: 22/34 health care services responded to the 
survey. 95% screen patients for cognitive and behavioural changes and all used the 
ECAS. Thematic analysis indicated that the ECAS: raises awareness about cognitive and 
behavioural change between patients, carers and healthcare professionals; validates 
and/or reassures; identifies changes, aids understanding of the patients’ presentation and 
informs clinical decision-making. The latter includes suitability of interventions, 
adaptations by the multidisciplinary team, discussions about end-of-life care, referral on 
to other services, and identifying carers’ support needs. A number of indirect economic 
benefits were described. Clinical neuropsychological intervention was reported to help 
the multidisciplinary team manage the care particularly of complex cases, the effects on 
daily life, and stress of patients, carers and families. Conclusions: The ECAS has been 
widely implemented across ALS health care teams in the UK. Screening for 
cognitive/behavioural deficits and neuropsychological intervention has a positive impact 
on patients, carers and healthcare professionals and improves the quality of routine 
clinical care.  
Keywords: Cognition; Neuropsychology: Assessment; Screening 
Word Count 3121 main text  
 
 
Introduction 
Approximately 50% of people with ALS will experience some degree of change in 
cognition and/or behaviour (Goldstein and Abrahams 2013). These changes have been 
shown to have consequences for clinical decision-making (Oliver and Turner 2010), 
patient adherence to life-prolonging interventions (Olney et al. 2005; Martin et al. 2014; 
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Govaarts et al.2017), and caregiver burden (Lillo et al. 2012, Andrew et al. 2017). In the 
UK, the National Institute for Health and Care Excellence (NICE) recently updated 
guidelines on the assessment and management of ALS which recommend that the 
multidisciplinary team should recognise, explore and assess changes in cognition and 
behaviour (NICE 2016). The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) 
is a multi-domain brief assessment developed for use by both neuropsychology and non-
neuropsychology health professionals and validated against extensive 
neuropsychological assessment with high sensitivity and specificity (Abrahams et al. 
2014; Niven et al. 2015; Pinto-Grau et al. 2017) and good convergent validity with other 
dementia screening measures (Lulé et al. 2014; Mora et al. 2018; Poletti et al. 2016). It 
was specifically designed for people with varying motor disability and can be undertaken 
in written and spoken forms. To date, the ECAS has been translated into 22 languages 
and is used by researchers and healthcare professionals around the world to screen people 
with ALS for changes in cognition and behaviour (https://ecas.psy.ed.ac.uk). Within the 
UK, effort has been made to educate ALS healthcare professionals about cognitive and 
behavioural symptoms and how to use the ECAS. Despite these advances, the clinical 
impact of implementing neuropsychological assessment and intervention in people with 
ALS has yet to be determined.  
 
The study aimed to evaluate the clinical impact of assessing cognitive and behavioural 
change using the ECAS. Specifically we undertook a mixed methods study (surveys and 
case study interviews) in order to evaluate: 
• Current practices in assessing cognitive and behavioural change in ALS 
and clinical utilisation of the ECAS in the UK; 
• The impact of implementing the ECAS on ALS patients, carers and 
healthcare professionals; and,  
A secondary aim was to evaluate the impact of clinical neuropsychological 
intervention on ALS care which was undertaken using case study interview alone. 
 
Materials and methods 
 
Survey 
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To assess current practices, ALS care services across the UK were asked to select an 
appropriate member of staff to complete a survey. This asked about: which screens for 
cognition and behaviour were being used; which healthcare professionals administered 
them; whether or not every patient was offered screening; and, the services patients were 
referred to if issues were detected (see supplementary materials). Thirty-four UK services 
(including care centres and other multidisciplinary models) were identified by the Motor 
Neurone Disease Association as specialising in ALS care and sent an online link to the 
survey between Jan-Jun 2018. One further invitation to complete the survey was sent by 
email if no response was received after the initial approach.. The online survey was 
created using Qualtrics software (Qualtrics, Provo, UT).  
 
Case Studies 
We used comparative case study methods to evaluate the impact of the ECAS and 
neuropsychological intervention. In our approach, a healthcare context was a ‘case’ and 
we aimed to explore the impact from a range of viewpoints in each context, including 
patients, carers and healthcare professionals. Contexts where the use of the ECAS was 
established were identified in England and Scotland. Purposive, heterogeneous sampling 
was employed to achieve variation between the seven contexts selected. Key features of 
variation, which formed the basis of selection, were informed by previous research 
(Crockford et al. 2017; Hodgins et al. 2018) and clinical experience. A description of each 
context (labelled A-G) and the key features on which they vary is shown in Table 1. Each 
health care context was asked to nominate appropriate participants and each of the 
patients nominated had to have undertaken an ECAS within the last 12 months. The 
nominated patients had undertaken an ECAS within 1, 2 and 12 months.  
 
Table 2 gives details of the case study participants within each healthcare context.  
 
 
This study was reviewed by the Department of Psychology, University of Edinburgh 
Ethics committee, the NHS Research Ethics Service and approved by Research and 
Development in each of the health boards/trusts where data collection took place. All 
participants have given written consent to the inclusion of material pertaining to 
themselves and acknowledged that the data is fully anonymised and cannot be identified.  
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[Insert Tables 1 and 2 here] 
 
Data were collected in semi-structured interviews either by telephone or face-to-face 
between December 2017 and June 2018. Interviews lasted approximately 45 minutes. 
Topic guides helped structure the interview and ensure main themes were covered (see 
supplementary material). Questions were derived from previous research and clinical 
insight into issues pertinent to screening and intervention in ALS care. One of the 
authors (FH) transcribed interview audio-recordings verbatim and subsequently checked 
the transcripts against the audio-recordings. The Framework Analysis method (Ritchie 
and Spencer 1994) was used to thematically analyse the data. This comprises five stages 
which were implemented in the following ways. 1. Familiarisation: The data was 
familiarised through the process of transcribing and checking the transcriptions against 
the original audio recordings and subsequently reading through the transcripts. 
2. Constructing a thematic framework: Through detailed examination of each transcript 
FH highlighted key concepts and potential themes. These were then organised to 
produce a hierarchical coding map. The coding was checked and refined following 
discussion with two other authors (SA and SM) 3. Indexing and sorting: The 
Framework Matrices function on NVivo 11 (QSR International Pte Ltd, Doncaster, 
Victoria, Australia) was used to link data (lines of the transcript) to relevant codes. 4. 
Data summarising and display: The NVivo software aided the organisation and 
summarisation of data in to rows (each row representing an interviewee) and columns 
(representing themes). Using NVivo software meant an electronic link between data 
summaries and the original transcripts was retained.  
5. Mapping and interpretation: Data in matrix rows and columns were compared, 
characteristics and differences between healthcare contexts were identified, and 
relationships were explored 
 
 
 
 
Results 
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Survey of current practices in cognitive screening in the UK 
Twenty-two ALS care services responded to the survey, (Non-responding care services 
included 3 MND care centres, 3 MND care networks/services, 5 community teams, 1 
hospice). Figure 1 shows that 95% of services screened patients for cognitive and 
behavioural change and all those used the ECAS to do so. Less than half of the services 
offered screening to every patient (45%). A majority of ALS services (90%) reported that 
they referred patients to clinical neuropsychology or another service (e.g. specialist 
geriatric service or psychology (clinical) service).  
 
[Insert Figure 1 here] 
 
Impact of cognitive and behavioural assessment using the ECAS 
 
 
The results of the interviews revealed that the ECAS was reported by participants to have 
an impact on health professionals, patients and carers in a number of ways which fall 
under the following overarching themes. 
 
1. Raises awareness that cognitive and behavioural change can be part of ALS. 
Patients and carers reported that the process of completing the ECAS ‘raised their 
awareness of the whole clinical picture’ (Care Network Coordinator, Context F) 
of ALS, including cognitive and behavioural change, and that without this 
opportunity to be informed, they ‘wouldn’t have even known that it was a factor’ 
(Patient, Context D).  
 
2. Reassures and/or validates  
None of the patients participating had cognitive or behavioural problems 
identified by the ECAS and described it as being ‘reassuring’ to have this 
confirmed. Healthcare professionals reported that those patients for whom the 
ECAS identified changes usually found this validating as they may have already 
noticed some difficulties themselves. Similarly, carers were described as finding 
the experience validating as the ECAS provided ‘objective rather than subjective’ 
(Occupational Therapist, Context G) evidence of changes and provided an 
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opportunity for carers to disclose related concerns. Furthermore undertaking the 
ECAS was reported to provide opportunity for the carer to disclose related 
concerns.  
 
3. Identifies changes and aids understanding of the patient’s presentation 
The ECAS was reported by healthcare professionals to help them identify changes 
that would otherwise go unnoticed. 
There are situations where, maybe because you don’t ask the right questions, 
maybe because you don’t listen to the answers…you may underestimate 
[changes] which an ECAS may then …pick up on (Consultant Neurologist, 
Context C).  
The ECAS was also reported to aid healthcare professionals in distinguishing 
between Alzheimer’s and Frontotemporal dementia in patients with ALS, 
We presume they’ve all got FTD but we’ve had a few patients who’ve had 
Alzheimer’s’ (Consultant Neurologist, Context D) 
and to contribute to an assessment of a patient’s capacity.   
It obviously gives you important insight into things like capacity which 
clearly is important when you’re discussing end-of-life care and other 
interventions (Consultant Neurologist, Context C) 
Healthcare professionals also reported using the ECAS results to understand 
whether cognitive and/or behavioural change could be the underlying cause of a 
patient’s unexpected or difficult-to-manage behaviour.  
[There was] a lady with challenging behaviour and increasingly poor 
communication and it was just very difficult to break down…is it MND, is 
it the fact that she’s in the care home and getting frustrated?...I wasn’t 
quite sure what I was going to find and the ECAS was actually really 
good…I think it helped us to exclude things that might be responsible 
Consultant in Palliative Care, Context G).  
 
4. ECAS informs clinical decision-making  
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The increased understanding of the patients’ presentation was reported to 
have an effect on a range of issues related to clinical decision-making (see 
Table 3).  
[Insert Table 3] 
 
5. Economic benefits of ECAS 
Two examples of indirect economic benefits to patients and families were mentioned by 
participants. One was the example of ECAS results being used as evidence of cognitive 
and/or behavioural change in order to make a stronger case when applying for continuing 
healthcare funding.  
We wouldn’t have got the funding if we hadn’t have had the ECAS score and it’s 
actually won them the funding’ (Care Coordinator, Context D). 
The second example was that a patient used their ECAS scores as evidence for 
their employer that they were cognitively fit to continue in their role.  
Economic benefits for care teams were also described. As the ECAS could be 
administered by a trained member of the multidisciplinary team, psychologists could 
focus their time on intervention work with patients and families. The psychologists were 
in agreement that the ECAS alone was sufficient for assessing cognitive/behavioural 
change in most ALS patients and use of the ECAS saved time they would otherwise spend 
administering a range of cognitive/behavioural assessments.  
 
6. Possible negative effects and how to minimize them  
Although the patients described the experience of completing the ECAS as ‘quite fun’ 
and not stressful, healthcare professionals and patients suggested that some patients could 
feel anxious about completing the ECAS, concerned about a poor performance, and 
burdened by news that they have cognitive and/or behavioural difficulties.  In addition, it 
was noted from the patients’ responses that they may not have fully understood the 
potential implications of doing an ECAS before agreeing to do it.  
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The healthcare professionals were in agreement that the ECAS was not harmful relative 
to other clinical assessments and interventions. It was even suggested that ‘there may be 
more harm in not doing it’ as changes in cognition or behaviour pertinent to future 
interventions or quality of life of the patient and carer may go unnoticed. 
However the following themes emerged from health professionals’ responses to minimize 
any possible negative effects:  
• consider the emotional state of the patient and do not ECAS ‘too soon’ after 
diagnosis; 
• explain what the ECAS is, why it is being offered, how the information gathered 
will be used, and give patients the option to accept or not; 
• emphasise what action will be taken if changes in cognition and/or behaviour are 
identified; and, 
• give patients feedback on the ECAS results in a timely, person-centred and 
meaningful way (i.e. do not use jargon such as ‘cut-off’ or give patients their raw 
ECAS scores but, rather, explain how the scores may relate to their everyday 
functioning).  
It was considered important to safeguard the interpretation of the ECAS by ensuring 
that a psychologist has input. Clinical neuropsychologists and clinical psychologists 
highlighted the potential risks of pathways to screening without input from psychology 
which included: 
• subtle qualitative information about how the patient reacted to the assessment and 
their general behaviour not being taken into account in interpretation leading to 
under/overestimation of deficits; 
• limited knowledge of how to adjust and interpret scores (or whether an ECAS is 
appropriate) in cases where patients have e.g. limited education or dyslexia, and, 
lack of reliability in administration as care team may not use the ECAS on a regular 
basis and therefore become de-skilled. 
 
Impact of neuropsychological intervention in ALS 
What is neuropsychological intervention in ALS? 
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The clinical neuropsychologists and clinical psychologists who participated in this study 
described their ALS-related work as involving an initial assessment of the patient, a 
formulation of the factors (physical, emotional, cognitive, behavioural, developmental) 
affecting how the patient presents, and, in Contexts A, C, D and E, subsequent 
intervention.  Interventions mentioned by psychologists included: 
• behavioural interventions- working with carers to implement strategies for 
managing challenging behaviour; 
• relational/family interventions- facilitating communication between family 
members to promote understanding and manage stressful situations; and, 
• interventions to improve emotional wellbeing and adjustment to living with the 
disease- e.g. mindfulness, Acceptance and Commitment Therapy, discussion of 
existential issues and the experience of dying. 
Impact of neuropsychological intervention on healthcare professionals 
Clinicalneuropsychological (or clinical psychology) input was reported by psychologists 
and other healthcare professionals to impact directly on healthcare teams in the following 
ways: 
• providing healthcare professionals with an understanding of a patient’s cognitive 
and behavioural status, enabling them to manage the patient more effectively; 
• providing support to an MDT, helping healthcare teams manage the stress of 
caring for patients and families; 
• being available for discussion of complex cases and referral for assessment and 
intervention, if required; 
• assisting with explanation of ECAS/other neuropsychological assessment results 
to patients and carers and how this relates to daily functioning and potential 
management strategies; and, 
advising on effective strategies for communicating with patients and carers.  
Discussion 
The study showed that the ECAS has been widely implemented across the UK. 
Ninety-five percent of ALS care services who responded screen ALS patients for 
cognitive and behaviour change and all use the ECAS. The patients, carers and health 
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professionals interviewed described that the process of completing an ECAS raises 
awareness of cognitive and behaviour change and that these symptoms form part of 
the whole clinical picture and provides an opportunity to discuss related concerns. It 
was seen to identify changes which may go unnoticed and aid in the understanding 
of the patients’ presentation, including determining why a patient may be behaving 
in a particular way and helping to assess capacity to make decisions.. The ECAS was 
also reported to be used to inform clinical decision-making by identifying changes 
that may otherwise go unnoticed, tailoring the types of intervention to the 
individual’s cognitive/behavioural problems (such as support with comprehension of 
guidance), and informing other health professionals on the suitability of interventions 
such as gastrostomy or non-invasive ventilation. It was also regarded as prompting 
early discussion of end of life care for those with cognitive/behavioural changes, 
indicating when referral to other services such as psychiatry is warranted and 
identifying when a carer may need support. As such administering a cognitive and 
behavioural screen was seen to improve the overall quality of routine clinical care 
The ECAS was also seen to validate both patients and carers experiences and to 
reassure those patients who were unimpaired. However it should be noted that this 
theme emerged mainly from a healthcare professionals perspective, which may have 
been due to the few number of carers and patients interview. Further benefits to patients 
were economic, such as using ECAS results to secure continuing healthcare funding and 
provide evidence to employers. In these ways, the ECAS indirectly benefits patients and 
their families. There were also economic benefits in psychologists’ time being saved 
through use of an efficient screen which can be administered by other trained members 
of the care team. Psychologists could focus their time on intervention work with 
patients and families. However, psychologists suggested that the feasibility of this 
arrangement would depend on the capability of the individual team member to conduct 
a reliable ECAS and that supervision would still take up some of their time.  
 
It is of note that fewer than half of the services offered screening to every patient 
(45%); most typically offering screening in cases where cognitive and/or behavioural 
change was suspected by a clinician. Given that most cognitive impairment in MND is 
mild and can be masked by physical disability it is possible that impairment may continue 
to go unrecognized in some people with MND.  
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Neuropsychological intervention was reported to impact on healthcare by 
enabling the understanding of patients’ cognitive and behavioural issues to help MDT 
with managing care, facilitating discussion of complex cases, helping the MDT manage 
stress from patients, carers and families, enabling the understanding of these changes in 
patients carers and families and how this affects daily life and management and advising 
on strategies 
.  
Some possible negative effects mentioned included anxiety over poor 
performance, burden of news of cognitive change and lack of understanding the 
implications of an assessment. In relation to managing these, two key themes emerged. 
Firstly, the need to incorporate supervision from a clinical neuropsychologist for 
interpretation of the ECAS in order to ensure the administration and interpretation is 
reliable and valid. Secondly, issues related to patient welfare including: the need to 
consider the timing of the administration of the screen in the patient’s care pathway; the 
importance of being transparent about the reasons for, and potential consequences, of 
screening; and, to consider how and when the patient will receive feedback on their 
results.  
We aimed to explore the impact of the ECAS and separately neuropsychological 
intervention from a range of perspectives in different healthcare contexts. With regard 
to the survey data we acknowledge that there is likely to have been a response bias with 
those who use the ECAS more likely to participate. Although 95% of respondent 
centres use the ECAS, this equates to 62% of the total who were approached including 
non-respondents. Furthermore within the time limits of the study, we were able to 
recruit key healthcare professionals involved in the implementation of the ECAS in 
each context; however, we were only able to recruit patients in three contexts and carers 
in two contexts. This led to the majority of our findings being informed by the 
perspective of healthcare professionals and it is possible that emergent themes would 
have been enriched with the inclusion of more patients and carers. Further work would 
benefit from more concentrated efforts to explore the perspectives of patients and 
carers. 
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Table 1. Description of each healthcare context included in the sample. 
 Scotland England 
 Context A 
MND Care 
Service in 
West (local) 
Context B 
MND Care 
Service in 
West 
(regional) 
Context C 
MND Care 
Service in 
East  
Context D 
MND Care 
Centre in 
North East  
Context E 
MND Care 
Centre in 
North  
Context F 
Team within  
MND Care 
Network, 
South East  
Context G 
Hospice 
Team, 
South  
Psychologist based within 
multidisciplinary clinic 
Yes       Yes   
ECAS usually administered by non-
psychology healthcare professional 
  Yes Yes  Yes Yes 
Psychologist interprets ECAS Yes Yes Yes  Yes   
Psychologist available for ECAS, 
further assessment and intervention 
Yes Yes Yes Yes Yes   
 
Psychologist: Clinical Psychologist or Clinical Neuropsychologist. MND Care centre is defined by the MNDA 
https://www.mndassociation.org/getting-support/care-centres/ 
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Table 2. Case study participants from each healthcare context (A-G). 
 
 
 
 
 
 
 
 
 
 
 
Context Participants 
A Clinical Neuropsychologist; Consultant Neurologist 
B Clinical Neuropsychologist; Clinical Psychologist; Consultant Neurologist (the same individual as Context A as they 
work across both areas) 
C Clinical Nurse Specialist; Clinical Neuropsychologist; Consultant Neurologist; Patient 
D Care Coordinator; Consultant Neurologist; Clinical Neuropsychologist; Patient; Carer 
E Clinical Psychologist; Assistant Psychologist 
F Care Network Coordinator 
G Consultant in Palliative Care; Occupational Therapist; Patient; Carer 
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Table 3. Impact of the ECAS on clinical decision-making. 
Impact of ECAS on 
clinical decision-making 
Example Quotation 
Informs healthcare 
professionals about the 
suitability of interventions 
(e.g. gastrostomy, Non-
invasive ventilation) 
‘… you’re probably being more proactive in terms of getting 
patients’ opinions of what they want done if there’s evidence of 
cognitive impairment…if people are likely to have significant 
behavioural disturbance and are not going to be able to manage 
to understand what a gastrostomy is or take part in it’ 
Consultant Neurologist, Context A & B 
The type of interventions 
may be tailored to their 
cognitive/behavioural 
status (e.g support with 
comprehension of 
guidance) 
‘If there [are] mild memory difficulties…we would... highlight 
that and say that this person might not remember all of their 
consultations so if you could give them written summaries…or 
if it’s fluency or language…adapt their communication style, 
slow things down, don’t overwhelm them with information’ 
Clinical Psychologist, Context B 
Prompts early discussion 
of end of life care for 
patients with 
cognitive/behavioural 
changes 
‘[people are] making very serious decisions quite quickly… we 
want to make sure they’re making choices that are right for 
them and that they can make those choices independently so, 
by finding out their cognitive state, it enables us to support 
them’ Consultant Neurologist, Context D 
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Care may be improved if 
other healthcare 
professionals are informed 
of changes in 
cognition/behaviour and 
advised on adjustments  
‘being able to flag up where someone might be having 
problems that people aren’t aware of to get them the right 
support, advice, to help make adjustments, support with 
decision-making’- Clinical Psychologist, Context E 
Indicates when referral to 
neuropsychology or 
psychiatry is necessary 
‘If there’s clearly other behavioural issues, we might want to 
involve psychology or psychiatry services in the community for 
behavioural management’ Consultant Neurologist, Context A & 
B 
Identifies cases where 
carer may need additional 
support, leading to 
signposting or referral to 
appropriate services (e.g. 
GP, counselling, clinical 
neuropsychology) 
‘[A patient] was not really eating and not taking her 
medication…she was really quite cognitively impaired and that 
allowed us to get more support …it alleviated the stress of the 
family because they were struggling…[it] was causing a lot of 
friction…We gave them strategies to help them get her to take 
her medicine and to eat but we also got psychiatric support in to 
support some of that activity and that .. allowed the family to 
continue it’- Clinical Neuropsychologist, Context B 
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Figure 1. Survey of cognitive and behavioural screening practices in the UK (Jan-Jun 2018). 
 
 
 
 
